JRS J. Rettenmaier & Söhne’s Post

Fedegari Group leads the way by partnering with ACE Technologies Group to create 𝗙𝗔𝗖𝗘, a revolutionary joint venture setting new sterilization standards in Asia. Combining Fedegari’s unmatched global expertise with ACE’s innovative engineering approach, FACE redefines pharmaceutical solutions, ensuring excellence and a superior customer experience. The Fedegari Tech Center in Singapore, a one-of-a-kind hub for ideas and innovation, strengthens Fedegari’s presence in Asia, bringing it even closer to its clients. This exciting venture will be officially presented at #CPHIIndia, with Stefano Nanni - Fedegari Group General Manager, Giacomo Rinaldi - Fedegari Managing Director Asia and ACE Managing Director Ajay Mehra in attendance. FACE is more than a partnership—it’s a bold step towards shaping the future of pharmaceutical manufacturing.

Our firm advised Pontika Aerotech Limited (Pontika) and its promoters on a primary investment by India SME Investments and other individual investors. Pontika, a leading CDMO, specializes in manufacturing and developing products across topical pharmaceuticals, beauty and personal care, and other niche segments, catering to major pharmaceutical and FMCG companies. The IndusLaw team included Partners Shantanu Jindel and Shweta Gupta, Senior Associates Harshit Kumar and Kriti Saraswat, and Associates Abhinav A. and Vatsal Agarwal. Learn more- https://lnkd.in/gyVP9B6h #IndusLaw #Deal #Investment #Pharmaceuticals #FMCG #PontikaAerotech

One week, two different continents 🌎 Join us in Denmark and South Korea for two much awaited events! 📍2024 PDA Parenteral Packaging Conference: 23 – 24 April,   Copenhagen, Denmark 🇩🇰  📍 Cophex 2024: 23 – 26 April, Goyang, South Korea 🇰🇷 Explore the future of pharma, packaging and biotech at these industry leading events and discover cutting-edge solutions that are sure to disrupt the industry’s paradigm and trigger innovation in your company. Whether it be in Denmark or South Korea, come meet our experts to learn about the latest pharma trends, discusse your company’s challenges and how we can help you move forward. Don’t miss on this chance! 🙌 Discover more about these events and, if you can’t meet us this week, check Körber Pharma’s upcoming events 👉 https://lnkd.in/dBdWwXR9 #cophex2024 #PDA #pharma #pharmaindustry #KörberPharma  

Doubling India’s Pharma Contract Manufacturing: Washington plans to double India’s pharma contract manufacturing within the next 3 years. Biosecure Act: The Act, which could be a game-changer for the Indian pharma industry, demands significant investment in infrastructure and talent. #PharmaIndustry #BiosecureAct #ContractManufacturing #USIndiaTrade #GlobalPharma

#Earnings Q3FY25 This quarter marked the completion of one year since the successful integration of the acquired  business. The business delivered a robust 14% year-on-year growth on a like-for-like basis,  underpinned by an increase in market shares in North America demonstrating strong customer  confidence and geographic expansion in Europe, and 14 launches in Emerging Markets. During the  quarter we received several regulatory approvals for our bUstekinumab, YESINTEK, including from the  U.S. FDA, Japan and a positive recommendation for approval by the CHMP to EMA. The U.S. FDA  classified our manufacturing facilities in India, and Malaysia, as VAI, thereby paving the way for new  product approvals in the United States. Several key milestones that we achieved this quarter will  consolidate the business and drive growth in the coming quarters." -- Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited. Read more: https://bit.ly/PR20250130

Strides Pharma gets USFDA nod for its drug to treat elevated phosphorous levels 💊What is the news buzz.? Strides Pharma Science Limited announced that their wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the drug to treat elevated phosphorous levels, from the USFDA. 💊What is the name of the drug.? Sevelamer Carbonate Tablets, 800 mg 💊What is the bioequivalent of this product.? According to the company the product is bioequivalent of Renvela Tablets, 800 mg, of Genzyme. 💊What is the market for this product.? According to the IMF Sevelamer Carbonate Tablets, 800 mg has a market size of ~US$ 181 Million. 💊Where will the product be manufactured ? The company has said that they will be manufactured at the company’s facility in Puducherry. I will provide the source of the article in the comment section below. By the way today is the 54th day of me deep diving into the pharmaceutical industry. I will be sharing insights from this industry on a regular basis. So please do follow me (Krishna Raj K) for such insights. #finance #Linkedin #India

Thoughts on this? >> Siegfried nabs US site from Curia; Merck KGaA pumps €62M more into its HQ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #biotech #pharmaceutical

At analytica Lab India, we hosted The Great Science Exchange, Agilent’s first panel discussion at an expo, featuring industry leaders Dr. Pratima Srivastava from Aragen Life Sciences and Dr. Balakumaran Kesavan, Aurigene Pharmaceutical Services Limited. They shared insights on automation, digitization, sustainability, and evolving pharma regulations like NDSRIs and USP <621>. Moderated by Lalit Hansoge with inputs from Kuldeep Sharma Ph.D, MBA, the session highlighted how Agilent supports pharma labs with innovation and regulatory readiness. We are grateful to our panelists for their expertise, as we remain committed to further partnerships with the industry to advance science and build a sustainable future together. Watch the full discussion here: https://lnkd.in/dyWN3_uG #AgilentIndia #IndiaLabExpo #GreatScience #LetsBringGreatSciencetoLife

🚀 Packaging Industry Breakthrough 🚀 In April 2024, IWK Packaging Systems, Inc. made waves with the launch of their CH 4 Cartoner. Designed to address the growing demands of pharmaceutical packaging, this high-speed solution stands out by cutting energy consumption by over 20%. The introduction of this technology is timely, as the pharmaceutical sector sees unprecedented growth, and efficiency remains a top priority. At Towards Packaging, we’re tracking how innovations like the CH 4 Cartoner are setting new standards for sustainability and performance in packaging. The cartoning machines market size to rise from US$ 8.72 bn in 2025 to US$ 11.15 bn by 2030. Asia Pacific led the market with the highest share in 2023 while Europe is expected to witness the highest CAGR during the forecast period. Stay connected with us for more industry insights and technological advancements! Source: https://lnkd.in/d8iKb_6N